Stock Analysis
DaVita Inc.DVA
P/E 14.10×· 5Y range 8.46–22.39×· 52th percentile of history
Sector: Healthcare · Industry: Services-Misc Health & Allied Services, Nec
AnalystsBuy13 analystsP/E 14.1× sits at the 52nd percentile of its 5.086926762491444-year history.
Cash covers 7% of debt · FY 2025.
PMP Verdict
Mixed fundamentals, fairly valued
Strengths
- Quality90
Risks
- Growth24
- Financial Health32
Mixed picture — no clear quality or value edge.
What's happening with DVA
Profile
Strong earnings quality and valuation; growth and financial health lag behind.
How is each axis scored?
- Valuation82/100 · Strong
- P/E vs own history (52th pct)12/25
- FCF yield (13.5%)25/25
- P/S (0.9x)25/25
- EV/EBIT (10.1x)20/25
- Growth24/100 · Weak
- Revenue CAGR (4.1%)6/25
- Net income CAGR (-6.5%)0/25
- EPS CAGR 5Y (2.5%)6/25
- Fwd implied growth (11.6%)12/25
- Profitability53/100 · Moderate
- ROIC (18.8%)20/25
- ROE (n/a)0/25
- Net margin (6.0%)13/25
- Operating margin (15.2%)20/25
- Financial Health32/100 · Weak
- Altman Z (1.73)10/25
- Current ratio (1.29)12/25
- Interest coverage (3.5x)10/25
- Net cash / debt (D/A 55%)0/25
- Quality90/100 · Strong
- Piotroski F (6/9)15/25
- Beneish M (-2.69)25/25
- FCF conversion (190%)25/25
- Margin stability (σ 2.7%)25/25
- Moat50/100 · Moderate
- ROIC >12% years (6/10 yrs)13/25
- Median gross margin (14.6%)0/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst 1.4%)12/25
Risk Flags
- ⚠Altman Z 1.7 — distress-zone balance sheet
About DaVita Inc.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. Show more
The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
Headquarters: DENVER, CO · Employees: 78,000 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
82AP/E (TTM)14.1xA
Grade A: CheapPrice / TTM EPS (own statements) — vs own 5Y history: 8.5x–22.4x · 52nd pct
P/FCF7.4xA
Grade A: CheapPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield13.5%A
Grade A: ValueTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 6.9%–19.4% · 63rd pct
P/S (TTM)0.85xA
Grade A: CheapPrice / TTM Revenue (own statements) — vs own 5Y history: 0.5x–1.2x · 49th pct
EV/EBIT10.1xA
Grade A: CheapEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 8.5x–14.7x · 17th pct
EV/Sales1.6xA
Grade A: CheapEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E12.6xA
Grade A: CheapPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B RatioNeg. EquityC
Grade C: BuybacksPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio0.97A
Grade A: CheapFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
53CROIC18.8%A
Grade A: MoatNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROENeg. EquityC
Grade C: BuybacksReturn on Equity. Neg. equity = heavy buybacks
ROA4.8%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin6.0%C
Grade C: AverageNet Income / Revenue
Operating Margin15.2%C
Grade C: AverageTTM EBIT / TTM Revenue
Gross Margin15.2%D
Grade D: LowGross Profit / Revenue
FCF Margin11.5%C
Grade C: AverageFCF / Revenue
True FCF Margin10.6%C
Grade C: AverageTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
24ERevenue CAGR4.1%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR-6.5%D
Grade D: LowCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)2.5%D
Grade D: LowCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth11.6%B
Grade B: LowAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-43.3%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income15.5%C
Grade C: MedStock-based comp/Net income. >30% = dilution risk
SBC / Revenue0.9%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
32DAltman Z-Score1.73D
Grade D: DistressBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio1.29xC
Grade C: OkCurrent Assets/Liabilities
Quick Ratio1.36xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage3.5xC
Grade C: OkEBIT/Interest. >10 Strong
Debt Repayment5.9yC
Grade C: AverageYears to repay net debt via FCF
Net Debt/EBIT4.5xD
Grade D: HighLeverage. <2x Low, >4x High
Debt/Equity—
Debt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.07xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
90A+Piotroski F-Score6/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-2.69A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion190.0%A
Grade A: StrongFCF / Net Income
Margin Stability2.7%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue4.2%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.80xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Maughan David Paul Filed | Maughan David Paul | Tax withholding | -7501 | |
Pullin Dennis W Filed | Pullin Dennis W | Grant / award | +278 | |
Moore Gregory J. Filed | Moore Gregory J. | Grant / award | +278 | |
Hollar Jason M. Filed | Hollar Jason M. | Grant / award | +278 | |
Arway Pamela M Filed | Arway Pamela M | Grant / award | +278 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Schechter Adam H Filed | Schechter Adam H | Grant / award | +278 | |
Schoppert Wendy Lee Filed | Schoppert Wendy Lee | Grant / award | +278 | |
YALE PHYLLIS R Filed | YALE PHYLLIS R | Grant / award | +278 |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
50CROIC >12% Years6/10 yrsC
Grade C: ModerateShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)14.6%D
Grade D: WeakMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor1.4%C
Grade C: ModerateWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$13.28
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$10.77
Cash & short-term investments per share (Finnhub)
Book Value / Share$1.50
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$10.27B
Total debt obligations (short + long term)
Cash & Equiv.$700.74M
Cash and short-term investments
Net Debt$9.57B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$-651.08M
Shareholders' equity (book value)
Asset / Liability1.07xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$11.95B
Current Market Capitalization
Beta0.88B
Grade B: MarketPrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: DaVita Inc. (DVA)
DVA is down 0.98% at the last close. Piotroski F-Score of 6/9 indicates mixed fundamentals for DaVita Inc.. Altman Z-Score of 1.73 is below the 1.81 distress threshold — an elevated financial-risk flag.
- Beneish M-Score of -2.69 suggests a low likelihood of earnings manipulation.
- Takes ~5.9 years to repay net debt from free cash flow.
- At a valuation score of 82/100, DVA trades near the cheapest end of its own historical range (P/E 14.1).
See how DVA ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all DVA moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 15 | Regular | 188.71 | +4.43% | 2.96 |
| Oct 15 | After-hours | 189.16 | +4.68% | 3.12 |
| Sep 24 | Regular | 175.36 | -4.25% | -2.22 |
| Sep 24 | After-hours | 174.67 | -4.62% | -2.42 |
| Sep 17 | Regular | 183.18 | -5.51% | -3.94 |
Frequently Asked Questions about DVA
What is the current DaVita Inc. (DVA) stock price?
DVA is trading at $187.31 at the last market close, down 0.98% on the session. PreMarketPrice tracks DVA pre-market, intraday and after-hours prices.
Is DVA stock a buy right now?
PreMarketPrice's quantitative model rates DaVita Inc.'s financial health at 32/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is DVA stock overvalued?
DaVita Inc. trades at a trailing P/E of 14.1 and our valuation score rates it 82/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does DaVita Inc. report earnings?
No confirmed earnings date is currently scheduled for DVA. The Earnings section lists recent reports and updates as dates are announced.
What sector does DaVita Inc. operate in?
DaVita Inc. operates in the Healthcare sector, within the Services-Misc Health & Allied Services, Nec industry. The Related Stocks section lists sector peers for comparison.
What does DaVita Inc. do?
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%.
About DaVita Inc. (DVA) Stock
DaVita Inc. (DVA) is a US-listed stock operating in the Healthcare sector, specifically the Services-Misc Health & Allied Services, Nec industry. As of the latest update, DaVita Inc. is trading at $187.31, down 0.98% on the day with a market capitalization of $11.9 billion. The financial health score for DVA is 32/100, which indicates weak financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for DVA stock.
DVA Stock Analysis & Key Metrics
On PreMarketPrice, you can track DaVita Inc. (DVA) across multiple dimensions:
- Pre-market price & movement: Real-time DVA stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for DVA with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for DaVita Inc. across multiple reporting periods.
- Financial health score: A composite score of 32/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for DVA.
- Sector peers: Compare DVA against 4 other healthcare stocks on key financial metrics.
Is DVA a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate DaVita Inc. (DVA) as an investment. The financial health score of 32/100 suggests weak financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.DaVita Inc. (DVA) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.